Sastasundar Ventures Limited has successfully concluded its postal ballot process and formally notified stock exchanges about the approved name change to Health X Platform Limited, marking a significant corporate transformation in the healthcare and digital platform space.

Postal Ballot Results Overview

The company conducted the postal ballot through remote e-voting process as per the notice dated January 7, 2026. The voting period commenced on January 15, 2026 at 9:00 a.m. and concluded on February 13, 2026 at 5:00 p.m. A total of 85 members representing 25,141,562 equity shares participated in the voting process.

Resolution 1: Company Name Change

The first special resolution sought approval for changing the company name from 'Sastasundar Ventures Limited' to 'Health X Platform Limited' along with consequential amendments to the Memorandum and Articles of Association. This resolution received exceptional support from shareholders across all categories.

Resolution 2: Memorandum Amendments

The second special resolution covered amendments to the Main Object Clause of the Memorandum of Association. The amendments include two new business objectives focused on healthcare and digital platform operations.

New Business Objectives

The approved amendments add two significant business verticals to the company's main objects. The new Object No. 7 enables the company to carry on healthcare, beauty care, personal care, pharmaceuticals, wellness, diagnostics, and food businesses including manufacturing, processing, marketing, trading, and distribution. Object No. 8 allows the company to design, develop, own, operate, and maintain digital platforms and e-commerce services, including marketplace operations, trading, order fulfillment, warehousing, logistics, and data management.

Regulatory Compliance and Implementation

Mr. Raj Kumar Bantia, Company Secretary in Practice, served as the scrutinizer and certified both resolutions were passed with requisite majority on February 13, 2026. The company has formally notified BSE Limited and National Stock Exchange of India Limited under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary Pratap Singh signed the regulatory disclosure, confirming compliance with all listing requirements. The detailed voting results and scrutinizer's report are available on the company's website at www.sastasundarventures.com .

Sastasundar Ventures Limited has reported its financial results for the quarter ended December 31, 2025, demonstrating a remarkable turnaround in consolidated performance despite ongoing challenges in its standalone operations. The company's Board of Directors approved the unaudited financial results during their meeting held on February 06, 2026.

Consolidated Financial Performance Shows Strong Recovery

The company's consolidated operations delivered impressive results for Q3FY26, marking a significant improvement over the previous year. The consolidated revenue from operations reached Rs 34,573.70 lakhs, showing growth from Rs 28,129.05 lakhs in Q3FY25.

The most significant achievement was the company's return to profitability at the consolidated level, with net profit after tax of Rs 36.87 lakhs compared to a substantial loss of Rs 3,779.18 lakhs in Q3FY25.

Nine-Month Performance Demonstrates Sustained Growth

For the nine months ended December 31, 2025, the consolidated performance showed strong momentum with revenue from operations of Rs 94,548.58 lakhs compared to Rs 82,511.41 lakhs in the corresponding period of FY25. The nine-month consolidated net profit stood at Rs 1,152.15 lakhs, a remarkable improvement from the loss of Rs 15,111.51 lakhs in the previous year.

Segment-wise Revenue Analysis

The company operates through two primary business segments, both contributing to the overall performance:

The Healthcare Network segment, which includes pathology, food processing, and marketing of healthcare products through e-commerce portals, remained the primary revenue driver. The Financial Services segment, encompassing loan financing, investment in securities, and wealth management services, showed significant growth during the quarter.

Standalone Operations Face Continued Challenges

While the consolidated results were encouraging, the standalone operations continued to face headwinds. The standalone revenue from operations declined to Rs 9.46 lakhs in Q3FY26 from Rs 10.72 lakhs in Q3FY25. The standalone net loss widened to Rs 40.99 lakhs compared to Rs 10.49 lakhs in the previous year's corresponding quarter.

Key Corporate Developments

During the reporting period, several significant corporate actions took place. Sastasundar Healthbuddy Limited, a material subsidiary, completed a buyback of 20,27,534 equity shares from Mitsubishi Corporation for Rs 10,000.00 lakhs in November 2025. This transaction increased the company's shareholding in Sastasundar Healthbuddy Limited from 72.14% to 78.89%.

Additionally, the sale of Happymate Foods Limited was completed on May 30, 2025, with the entity ceasing to be a subsidiary of Sastasundar Healthbuddy Limited from that date.

Financial Position and Outlook

The company maintained a paid-up equity share capital of Rs 3,181.05 lakhs with a face value of Rs 10.00 per share. The consolidated total assets stood at Rs 87,237.13 lakhs as of December 31, 2025, compared to Rs 95,873.00 lakhs in the previous year. The results were reviewed by the Audit Committee and approved by the Board of Directors, with statutory auditors J K V S & C O providing limited review reports for both standalone and consolidated financial statements.